Neither cagrilintide nor retatrutide is FDA approved as of early 2026
While these findings are biologically plausible, they should be interpreted with caution and considered hypothesis-generating rather than confirmatory
While the doses were different, these results were echoed in a recent study
If your body is still: Inflamed Nutrient deficient Dependent on processed foods Youre not building long-term healthyoure just suppressing appetite
This was markedly longer than in the other CVOTs where the median follow-up ranged from 1.3 to 3.8 years and perhaps suggesting enrollment of predominantly low-risk patients in REWIND as a possible limitation
Participants with a BMI just outside this range, whether lower or higher, may still benefit from CT-868, but their response could be different, affecting reproducibility in the wider T1DM population